Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.

George SL, Izquierdo E, Campbell J, Koutroumanidou E, Proszek P, Jamal S, Hughes D, Yuan L, Marshall LV, Carceller F, Chisholm JC, Vaidya S, Mandeville H, Angelini P, Wasti A, Bexelius T, Thway K, Gatz SA, Clarke M, Al-Lazikani B, Barone G, Anderson J, Tweddle DA, Gonzalez D, Walker BA, Barton J, Depani S, Eze J, Ahmed SW, Moreno L, Pearson A, Shipley J, Jones C, Hargrave D, Jacques TS, Hubank M, Chesler L.

Eur J Cancer. 2019 Sep 11. pii: S0959-8049(19)30446-0. doi: 10.1016/j.ejca.2019.07.027. [Epub ahead of print]

2.

Species succession and the development of a lacustrine fish community in an ephemeral lake.

Peel RA, Hill JM, Taylor GC, Tweddle D, Weyl OLF.

J Fish Biol. 2019 Sep;95(3):855-869. doi: 10.1111/jfb.14081. Epub 2019 Jul 19.

PMID:
31219181
3.

The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression.

Hawley J, Veal GJ, Errington J, McDonald LG, Tweddle DA.

Pediatr Blood Cancer. 2019 Sep;66(9):e27825. doi: 10.1002/pbc.27825. Epub 2019 May 28.

PMID:
31135092
4.

A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma.

Herd F, Basta NO, McNally RJQ, Tweddle DA.

Eur J Cancer. 2019 Apr;111:50-58. doi: 10.1016/j.ejca.2018.12.032. Epub 2019 Feb 26. Review.

5.

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.

Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, Thomas HD, Zhao Y, Daga A, Veal GJ, Lunec J, Newell DR, Ponzoni M, Tweddle DA.

Int J Cancer. 2019 Jun 15;144(12):3146-3159. doi: 10.1002/ijc.32058. Epub 2019 Jan 9.

6.

Differentiation of Human Embryonic Stem Cells to Sympathetic Neurons: A Potential Model for Understanding Neuroblastoma Pathogenesis.

Carr-Wilkinson J, Prathalingam N, Pal D, Moad M, Lee N, Sundaresh A, Forgham H, James P, Herbert M, Lako M, Tweddle DA.

Stem Cells Int. 2018 Nov 1;2018:4391641. doi: 10.1155/2018/4391641. eCollection 2018.

7.

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.

Chen L, Esfandiari A, Reaves W, Vu A, Hogarty MD, Lunec J, Tweddle DA.

Int J Oncol. 2018 Mar;52(3):967-977. doi: 10.3892/ijo.2018.4261. Epub 2018 Jan 31.

PMID:
29393340
8.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
9.

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.

Chen L, Humphreys A, Turnbull L, Bellini A, Schleiermacher G, Salwen H, Cohn SL, Bown N, Tweddle DA.

Oncotarget. 2016 Dec 27;7(52):87301-87311. doi: 10.18632/oncotarget.13541.

10.

Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.

Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, Elliott M, Moreno L, Barone G, Pearson AD, James PW, Tweddle DA, McNally RJ.

Br J Cancer. 2016 Oct 25;115(9):1048-1057. doi: 10.1038/bjc.2016.302. Epub 2016 Oct 4.

11.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

12.

Temporal clustering of neuroblastic tumours in children and young adults from Northern England.

Muirhead CR, Tweddle DA, Basta NO, McNally RJ.

Environ Health. 2015 Sep 4;14:72. doi: 10.1186/s12940-015-0058-z.

13.

Carboplatin therapeutic monitoring in preterm and full-term neonates.

Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RM, Tweddle DA, Jenkinson H, Picton S.

Eur J Cancer. 2015 Sep;51(14):2022-30. doi: 10.1016/j.ejca.2015.07.011. Epub 2015 Jul 29.

14.

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.

Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, Tweddle DA.

Oncotarget. 2015 Apr 30;6(12):10207-21.

15.

SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.

Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, Newell DR, Tweddle DA.

Cancer Lett. 2015 Jul 10;363(1):37-45. doi: 10.1016/j.canlet.2015.03.044. Epub 2015 Apr 2.

PMID:
25843293
16.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

17.

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.

Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA.

Br J Cancer. 2014 Aug 12;111(4):716-25. doi: 10.1038/bjc.2014.325. Epub 2014 Jun 12.

18.

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib.

Bell E, Ponthan F, Whitworth C, Tweddle DA, Lunec J, Redfern CP.

Clin Exp Metastasis. 2014 Aug;31(6):651-9. doi: 10.1007/s10585-014-9656-3. Epub 2014 May 25.

PMID:
24859418
19.

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.

Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T.

Curr Drug Targets. 2014 Jan;15(1):114-23. Review.

PMID:
24387312
20.
21.

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Chen L, Tweddle DA.

Front Oncol. 2012 Nov 28;2:173. doi: 10.3389/fonc.2012.00173. eCollection 2012.

22.

Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation.

Sung PJ, Boulos N, Tilby MJ, Andrews WD, Newbold RF, Tweddle DA, Lunec J.

Cancer Lett. 2013 Jan 1;328(1):168-75. doi: 10.1016/j.canlet.2012.08.015. Epub 2012 Aug 17.

PMID:
22906418
23.

The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, Cialfi S, Vergalli J, Fragliasso V, Guerzoni C, Manzotti G, Soliera AR, Menin C, Bertorelle R, McDowell HP, Inserra A, Belli ML, Varesio L, Tweddle D, Tonini GP, Altavista P, Dominici C, Raschellà G, Calabretta B.

Neoplasia. 2012 Jul;14(7):634-43.

24.

Neonatal neuroblastoma.

Fisher JPH, Tweddle DA.

Semin Fetal Neonatal Med. 2012 Aug;17(4):207-215. doi: 10.1016/j.siny.2012.05.002. Epub 2012 Jun 4. Review.

PMID:
22673527
25.

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Bénard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Cañete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J.

Br J Cancer. 2011 Dec 6;105(12):1940-8. doi: 10.1038/bjc.2011.472. Epub 2011 Nov 10.

26.

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

Carr-Wilkinson J, Griffiths R, Elston R, Gamble LD, Goranov B, Redfern CP, Lunec J, Tweddle DA.

Cell Cycle. 2011 Nov 1;10(21):3778-87. doi: 10.4161/cc.10.21.17973. Epub 2011 Nov 1.

PMID:
22052359
27.

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Gamble LD, Kees UR, Tweddle DA, Lunec J.

Oncogene. 2012 Feb 9;31(6):752-63. doi: 10.1038/onc.2011.270. Epub 2011 Jul 4.

28.

A multilocus technique for risk evaluation of patients with neuroblastoma.

Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF.

Clin Cancer Res. 2011 Feb 15;17(4):792-804. doi: 10.1158/1078-0432.CCR-10-0830.

29.

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.

Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA.

Pediatr Hematol Oncol. 2011 Mar;28(2):106-14. doi: 10.3109/08880018.2010.526684. Epub 2011 Jan 8.

PMID:
21214410
30.

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ.

Br J Cancer. 2010 Nov 9;103(10):1588-96. doi: 10.1038/sj.bjc.6605946. Epub 2010 Oct 26.

31.

The impact of conservation on the status of the world's vertebrates.

Hoffmann M, Hilton-Taylor C, Angulo A, Böhm M, Brooks TM, Butchart SH, Carpenter KE, Chanson J, Collen B, Cox NA, Darwall WR, Dulvy NK, Harrison LR, Katariya V, Pollock CM, Quader S, Richman NI, Rodrigues AS, Tognelli MF, Vié JC, Aguiar JM, Allen DJ, Allen GR, Amori G, Ananjeva NB, Andreone F, Andrew P, Aquino Ortiz AL, Baillie JE, Baldi R, Bell BD, Biju SD, Bird JP, Black-Decima P, Blanc JJ, Bolaños F, Bolivar-G W, Burfield IJ, Burton JA, Capper DR, Castro F, Catullo G, Cavanagh RD, Channing A, Chao NL, Chenery AM, Chiozza F, Clausnitzer V, Collar NJ, Collett LC, Collette BB, Cortez Fernandez CF, Craig MT, Crosby MJ, Cumberlidge N, Cuttelod A, Derocher AE, Diesmos AC, Donaldson JS, Duckworth JW, Dutson G, Dutta SK, Emslie RH, Farjon A, Fowler S, Freyhof J, Garshelis DL, Gerlach J, Gower DJ, Grant TD, Hammerson GA, Harris RB, Heaney LR, Hedges SB, Hero JM, Hughes B, Hussain SA, Icochea M J, Inger RF, Ishii N, Iskandar DT, Jenkins RK, Kaneko Y, Kottelat M, Kovacs KM, Kuzmin SL, La Marca E, Lamoreux JF, Lau MW, Lavilla EO, Leus K, Lewison RL, Lichtenstein G, Livingstone SR, Lukoschek V, Mallon DP, McGowan PJ, McIvor A, Moehlman PD, Molur S, Muñoz Alonso A, Musick JA, Nowell K, Nussbaum RA, Olech W, Orlov NL, Papenfuss TJ, Parra-Olea G, Perrin WF, Polidoro BA, Pourkazemi M, Racey PA, Ragle JS, Ram M, Rathbun G, Reynolds RP, Rhodin AG, Richards SJ, Rodríguez LO, Ron SR, Rondinini C, Rylands AB, Sadovy de Mitcheson Y, Sanciangco JC, Sanders KL, Santos-Barrera G, Schipper J, Self-Sullivan C, Shi Y, Shoemaker A, Short FT, Sillero-Zubiri C, Silvano DL, Smith KG, Smith AT, Snoeks J, Stattersfield AJ, Symes AJ, Taber AB, Talukdar BK, Temple HJ, Timmins R, Tobias JA, Tsytsulina K, Tweddle D, Ubeda C, Valenti SV, van Dijk PP, Veiga LM, Veloso A, Wege DC, Wilkinson M, Williamson EA, Xie F, Young BE, Akçakaya HR, Bennun L, Blackburn TM, Boitani L, Dublin HT, da Fonseca GA, Gascon C, Lacher TE Jr, Mace GM, Mainka SA, McNeely JA, Mittermeier RA, Reid GM, Rodriguez JP, Rosenberg AA, Samways MJ, Smart J, Stein BA, Stuart SN.

Science. 2010 Dec 10;330(6010):1503-9. doi: 10.1126/science.1194442. Epub 2010 Oct 26.

32.

MYCN oncoprotein targets and their therapeutic potential.

Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA.

Cancer Lett. 2010 Jul 28;293(2):144-57. doi: 10.1016/j.canlet.2010.01.015. Epub 2010 Feb 13. Review.

PMID:
20153925
33.

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NK, Boos J, Köhler G, Leuschner I, Pearson AD, Lunec J, Tweddle DA.

Clin Cancer Res. 2010 Feb 15;16(4):1108-18. doi: 10.1158/1078-0432.CCR-09-1865. Epub 2010 Feb 9.

34.

p53 is a direct transcriptional target of MYCN in neuroblastoma.

Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA.

Cancer Res. 2010 Feb 15;70(4):1377-88. doi: 10.1158/0008-5472.CAN-09-2598. Epub 2010 Feb 9.

35.

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC.

Clin Cancer Res. 2009 Feb 15;15(4):1241-9. doi: 10.1158/1078-0432.CCR-08-1095. Epub 2009 Jan 27.

36.

Histological profile of tumours from MYCN transgenic mice.

Moore HC, Wood KM, Jackson MS, Lastowska MA, Hall D, Imrie H, Redfern CP, Lovat PE, Ponthan F, O'Toole K, Lunec J, Tweddle DA.

J Clin Pathol. 2008 Oct;61(10):1098-103. doi: 10.1136/jcp.2007.054627. Epub 2008 Aug 4.

PMID:
18682419
37.

p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma.

Chen L, Malcolm AJ, Wood KM, Cole M, Variend S, Cullinane C, Pearson AD, Lunec J, Tweddle DA.

Cell Cycle. 2007 Nov 1;6(21):2685-96. Epub 2007 Aug 10.

PMID:
17912039
38.

Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.

Łastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, Jackson MS.

Oncogene. 2007 Nov 22;26(53):7432-44. Epub 2007 May 28.

PMID:
17533364
39.

Cell cycle regulation targets of MYCN identified by gene expression microarrays.

Bell E, Lunec J, Tweddle DA.

Cell Cycle. 2007 May 15;6(10):1249-56. Epub 2007 May 1.

PMID:
17495526
40.

High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays.

Carr J, Bown NP, Case MC, Hall AG, Lunec J, Tweddle DA.

Cancer Genet Cytogenet. 2007 Jan 15;172(2):127-38.

PMID:
17213021
41.

The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.

Bell E, Premkumar R, Carr J, Lu X, Lovat PE, Kees UR, Lunec J, Tweddle DA.

Cell Cycle. 2006 Nov;5(22):2639-47. Epub 2006 Nov 15.

PMID:
17172827
42.

Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow.

Bomken SN, Redfern K, Wood KM, Reid MM, Tweddle DA.

J Clin Pathol. 2006 Sep;59(9):927-9. Epub 2006 Mar 24.

43.

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.

Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, Tweddle DA.

Cancer Res. 2006 Feb 15;66(4):2138-45.

44.

MYCN amplification remains prognostically strong 20 years after its "clinical debut".

Cohn SL, Tweddle DA.

Eur J Cancer. 2004 Dec;40(18):2639-42. No abstract available.

PMID:
15571946
45.

Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior.

Tornóczky T, Kálmán E, Kajtár PG, Nyári T, Pearson AD, Tweddle DA, Board J, Shimada H.

Cancer. 2004 Jan 15;100(2):390-7.

46.

Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.

Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, Board J, George RE, Ellershaw C, Pearson AD, Lunec J, Montaldo PG, Ponzoni M, van Eck-Smit BL, Hoefnagel CA, van den Brug MD, Tytgat GA, Caron HN.

Clin Cancer Res. 2003 Aug 15;9(9):3338-44.

47.

The p53 pathway and its inactivation in neuroblastoma.

Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J.

Cancer Lett. 2003 Jul 18;197(1-2):93-8. Review.

PMID:
12880966
48.

OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.

Tweddle DA, Pinkerton CR, Lewis IJ, Ellershaw C, Cole M, Pearson AD.

Med Pediatr Oncol. 2001 Jan;36(1):239-42.

PMID:
11464894
49.
50.

Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line.

Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J.

Cancer Res. 2001 Jan 1;61(1):8-13.

Supplemental Content

Loading ...
Support Center